Nasopharyngeal carcinoma: alternative treatment options after disease progression

References

• Levine PH, Conelly RR. Epidemiology of nasopharyngeal cancer. Head Neck Cancer83(1), 13–34 (1985).
   Google Scholar
• Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.4, 183–188 (1978).
   Web of Science ®Google Scholar
• Muir CS, Waterhouse J, Mack T. Cancer incidence in five continents. In: IARC Science Publications (volume 88). IARC, Lyon, France (1987).
   Google Scholar
• Chan AT, Teo PM, Johnson PJ. Nasopharyngeal cancer. Cancer Treat. Res.114, 275–293 (2003).
   PubMedGoogle Scholar
• Anderson-Anvret M, Forsby N, Klein G. Relation between the EBV and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and hystopathological examination. Int. J. Cancer.20, 486–494 (1977).
   PubMedGoogle Scholar
• Raab Traub N, Flynn K. The structure of the termini of the Epstein–Barr virus as a marker of clonal proliferation. Cell47, 883–889 (1986).
   PubMed Web of Science ®Google Scholar
• Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer Epidemiol. Biomarkers Prev.17, 2356–2365 (2008).
   PubMedGoogle Scholar
• Bosq J, Gatter KC, Micheau C, Mason DY. Role of immunohistochemistry in diagnosis of nasopharyngeal tumour. J. Clin. Pathol.38, 845–848 (1985).
   PubMedGoogle Scholar
• Gusterson BA, Mitchell DP, Warburton MJ, Carter RL. Epithelial markers in the diagnosis of nasopharyngeal carcinoma. An immunocytochemical study. J. Clin. Pathol.36, 628–631 (1983).
   PubMedGoogle Scholar
• Miettinen M, Lehto VP, Virtanen I. Nasopharyngeal lymphoepithelioma. Histological diagnosis as aided by immunohistochemical demonstration of keratin. Virchows Arch. Cell. Pathol.40, 163–169 (1982).
   Google Scholar
• Oppedal BR, Bohler PJ, Marton PF, Brandtzaeg P. Carcinoma of the nasopharynx. Histopathological examination with supplementary immunohistochemistry. Histopathology11, 1161–1169 (1987).
   PubMedGoogle Scholar
• Lauriola L, Michetti F, Sentinelli S, Cocchia D. Detection of S-100 labelled cells in nasopharyngeal carcinoma. J. Clin. Pathol.37, 1235–1238 (1984).
   PubMed Web of Science ®Google Scholar
• Batsakis JG, Solomon AR, Rice DH. The pathology of head and neck tumors. Carcinoma of the nasopharynx. Head Neck Surg.3, 511–524 (1981).
   PubMedGoogle Scholar
• Leung SY, Chau JY, Yuen ST. P53 overexpression is different in Epstein–Barr virus-negative carcinoma. Histopathology33, 311–317 (1998)
   PubMedGoogle Scholar
• Murono S, Yoshizaki T, Park CS, Furukawa M. Association of Epstein–Barr virus infection with P53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology34, 432–438 (1999).
   PubMedGoogle Scholar
• Fan CS, Wong N, Leung SF et al. Frequent c-myc and Int-2 overrepresentation in nasopharyngeal carcinoma. Hum. Pathol.31, 169–178 (2000).
   PubMed Web of Science ®Google Scholar
• Gulley ML, Nicholls JM, Schnieder BG, Amin MB, Ro JY, Geradts J. Nasopharyngeal carcinoma frequently lack p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am. J. Pathol.152, 865–869 (1998).
   PubMedGoogle Scholar
• Schminke A. Ueber lymphoepitheliale geschwulster Beiter. Pathol. Anat.58, 161–170 (1921).
   Google Scholar
• Regaud C, Reverchon L. Sur un cas dépithelioma epidermoide developpe Dans le massif maxillaire superieur etendu au ligaments de la face, aux cavites buccale, nasale et orbitaire ainsi quáux ganglions du cou gueri par la radiotherapie. Rev. Laryngol.42, 3 (1921).
   Google Scholar
• Zornoza J, Gangir A, Green B. Hyperthrophic osteoarthropathy associated with nasopharyngeal carcinoma. Am. J. Roent.128, 676–681 (1977).
   Google Scholar
• Cvitkovic E, Bachouchi M, Boussen H et al. Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases. J. Clin. Oncol.11, 2434–2442 (1993).
   PubMedGoogle Scholar
• Fong KW, Chua EJ, Chua ET et al. Patient profile and survival in 270 computer tomography-staged patients with nasopharyngeal cancer treated at the Singapore General Hospital. Ann. Acad. Med. Singapore25, 341–346 (1996).
   PubMedGoogle Scholar
• Heng DW, Wee J, Fong KW et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer86, 1912–1920 (1999).
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol.16(4), 1310–1317 (1998).
   PubMed Web of Science ®Google Scholar
• Ong YK, Heng DM, Chung B et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur. J. Cancer39, 1535–1541 (2003).
   PubMedGoogle Scholar
• Cheng SH, Tsai SY, Yen KL et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J. Clin. Oncol.18, 2040–2045 (2000).
   PubMed Web of Science ®Google Scholar
• Chan AT, Teo PM, Leung TW et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.33, 569–577 (1995).
   PubMedGoogle Scholar
• Chen KY, Fletcher GH. Malignant tumour of the nasopharynx. Radiology99, 165–171 (1971).
   PubMed Web of Science ®Google Scholar
• Choy D, Sham JS, Wei WI, Ho CM, Wu PM. Transpalatal insertion of gold grain for the treatment of persistent and recurrent nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Bio. Phys.25, 505–512 (1993).
   PubMed Web of Science ®Google Scholar
• Fee WE, Robertson JB, Goffinet DR. Long term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure. Arch. Otolaryngol. Head Neck Surg.117, 1233–1236 (1991).
   PubMedGoogle Scholar
• Hoppe RT, Goffinet DR, Bagshaw MA. Carcinoma of the nasopharynx: eighteen years experience with megavoltage radiation therapy. Cancer37, 2605–2612 (1976).
   PubMed Web of Science ®Google Scholar
• Lee AW, Law SC, Foo W et al. Retrospective analysis of patients with nasopharyngeal carcinoma treated during 1976–1985: survival after local recurrence. Int. J. Radiat. Oncol. Bio. Phys.26, 773–782 (1993).
   PubMed Web of Science ®Google Scholar
• Sham JS, Wei WI, Choy D, Ho CM, Tai PT, Choi PH. Treatment of persistent and recurrent nasopharyngeal carcinoma by brachytherapy. Br. J. Radiol.62, 355–361 (1989).
   PubMed Web of Science ®Google Scholar
• Vikram B, Hilaris B. Transnasal permanent intersticial implantation for carcinoma of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys.10, 153–155 (1984).
   PubMed Web of Science ®Google Scholar
• Zhang EP, Lian PG, Cai KL et al. Radiation therapy of nasopharyngeal carcinoma: prognostic factors based on a 10 year follow up of 1302 patients. Int. J. Radiat. Oncol. Bio. Phys.16, 301–305 (1989).
   PubMed Web of Science ®Google Scholar
• Lee AW, Foo W, Law SC et al. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways to improvement. Int. J. Radiat. Oncol. Bio. Phys.38, 43–52 (1997).
   PubMed Web of Science ®Google Scholar
• Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Bio. Phys.41, 109–111 (1998).
   PubMedGoogle Scholar
• Wang CC. Reirradiation of recurrent nasopharyngeal carcinoma: treatment techniques and results. Int. J. Radiat. Oncol. Bio. Phys.13, 953–956 (1987).
   PubMed Web of Science ®Google Scholar
• Lee AW, Sham JS, Poon YF, Ho JH et al. Treatment of stage I nasopharyngeal carcinoma: analysis of the patterns of relapse and the results of withholding elective neck irradiation. Int. J. Radiat. Oncol. Bio. Phys.17, 1183–1190 (1989).
   PubMed Web of Science ®Google Scholar
• Kwong DL, Wei WI, Cheng AC et al. Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma. Cancer91, 1105–1113 (2001).
   PubMed Web of Science ®Google Scholar
• Law SC, Lam WK, Ng MF, Au SK, Mak WT, Lau WH. Reirradiation of nasopharyngeal carcinoma with intracavitary mold brachytherapy: an effective means of local salvage. Int. J. Radiat. Oncol. Bio. Phys.54, 1095–1113 (2002).
   PubMedGoogle Scholar
• Buatti JM, Friedman WA, Bova FJ, Mendenhall WM. LINAC radiosurgery for locally recurrent nasopharyngeal carcinoma: rationale and technique. Head Neck17, 14–19 (1995).
   PubMed Web of Science ®Google Scholar
• Cmelak AJ, Cox RS, Adler JR, Fee WE, Goffinet DR. Radiosurgery for skull base malignancies and nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.37, 997–1003 (1997).
   PubMedGoogle Scholar
• Kaplan ID, Adler JR, Hicks WL, Fee WE, Goffinet DR. Radiosurgery for palliation of skull base recurrence from head and neck cancers. Cancer70, 1980–1984 (1992).
   PubMedGoogle Scholar
• Pai PC, Chuang CC, Wei KC, Tsang NM, Tseng CK, Chang CN. Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck24, 748–753 (2002).
   PubMed Web of Science ®Google Scholar
• Low JS, Chua ET, Gao F, Wee JT. Stereotactic radiosurgery plus intracavitary irradiation in the salvage of nasopharyngeal carcinoma. Head Neck28, 321–329 (2006).
   PubMedGoogle Scholar
• Lu TX, Mai WY, Teh BS et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.58, 682–687 (2004).
   PubMed Web of Science ®Google Scholar
• King WW, Ku PK, Mok CO, Teo PM. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve year experience. Head Neck22, 215–222 (2000).
   PubMed Web of Science ®Google Scholar
• Teo PM, Kwan WH, Chan AT, Lee WY, King WW, Mok CO. How successful is high dose (>60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int. J. Radiat. Oncol. Biol. Phys.40, 897–913 (1998).
   PubMed Web of Science ®Google Scholar
• Yao YZ. Reirradiation of recurrent nasopharyngeal carcinoma-analysis of 58 cases. Chung Hua Chung Liu Tsa Chih288–290 (1989).
   Google Scholar
• Nageris B, Lavelle W, Elidan J. Multiple late complications of irradiation treatment of nasopharyngeal carcinoma. Ear Nose Throat J.74, 286–288 (1995).
   PubMedGoogle Scholar
• Tu GY, Hu YH, Xu GZ, Ye M. Salvage surgery for nasopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg.114, 328–329 (1988).
   PubMedGoogle Scholar
• Fee WE, Gilmer PA, Goffinet DR. Surgical management of recurrent nasopharyngeal carcinoma after radiation failure at the primary site. Laryngoscope98, 1220–1226 (1988).
   PubMed Web of Science ®Google Scholar
• Wei WI, Lam KH, Sham JS. New approach to the nasopharynx. The maxillary swing approach. Head Neck13, 200–207 (1991).
   PubMed Web of Science ®Google Scholar
• Hsu MM, Ko JY, Sheen TS, Chang YL. Salvage surgery for recurrent nasopharyngeal carcinoma. Arch. Otoloryngol. Head Neck Surg.123, 305–309 (1997).
   PubMedGoogle Scholar
• Morton RP, Liavaag PG, McLean M, Freeman JL. Transcervico–mandibulo–palatal approach for surgical salvage of recurrent nasopharyngeal cancer. Head Neck18, 352–358 (1996).
   PubMed Web of Science ®Google Scholar
• To EW, Teo PM, Ku PK, Pang PC. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: an innovative transnasal approach through a mid face deglove incision with stereotactic navigation guidance. Br. J. Oral Maxillofac. Surg.39, 55–62 (2001).
   PubMedGoogle Scholar
• Fee WE, Moir MS, Choi EC, Goffinet D. Nasopharyngectomy for recurrent nasopharyngeal cancer. A 2 to 17 year follow up. Arch. Otolaryngol. Head NeckSurg.128, 280–284 (2002).
   PubMedGoogle Scholar
• Bedwinek JM, Perez CA, Keys DJ. Analysis of failure after definitive irradiation for epidermoid carcinoma of the nasopharynx. Cancer45, 2725–2729 (1980).
   PubMed Web of Science ®Google Scholar
• Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan: clinical manifestations and results of therapy. Cancer52, 362–368 (1983).
   PubMed Web of Science ®Google Scholar
• Chen WZ, Zhou DL, Luo KS. Long-term observation after radiotherapy for nasopharyngeal carcinoma (NPC). Int. J. Radiat. Oncol. Biol. Phys.16, 311–314 (1989).
   PubMed Web of Science ®Google Scholar
• Wei WI, Lam KH, Ho CM, Sham JT, Lau SK. Efficacy of radical neck dissection for the control of cervical metastasis after radiotherapy for nasopharyngeal carcinoma. Am. J. Surg.160, 439–442 (1990).
   PubMedGoogle Scholar
• Yen KL, Hsu LP, Sheen TS, Chang YL, Hsu MM. Salvage neck dissection for cervical recurrence of nasopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg.123, 725–729 (1997).
   PubMedGoogle Scholar
• Chen MK, Lai JC, Chang CC, Liu MT. Minimally invasive endoscopic nasopharyngectomy in the treatment of recurrent T1–2a nasopharyngeal carcinoma. Laryngoscope117, 894–896 (2007).
   PubMedGoogle Scholar
• Chen MY, Wen WP, Guo X et al. Endoscopic nasopharyngectomy for locally recurrent nasopharyngeal carcinoma. Laryngoscope119, 516–522 (2009).
   PubMed Web of Science ®Google Scholar
• Ko JY, Wang CP, Ting LL, Yang TL, Tan CT. Endoscopic nasopharyngectomy with potassium-titanyl-phosphate (KTP) laser for early locally recurrent nasopharyngeal carcinoma. Head Neck31(10), 1309–1315 (2009).
   PubMedGoogle Scholar
• Chan SH, Goh EH, Khor TH, Chew TS. General immunological status of nasopharyngeal carcinoma patients in Singapore. IARC Sci. Publ.20, 495–501 (1978).
   Google Scholar
• Chan AT, Teo ML, Lee WY, Kwan WH, Choi PH, Johnson PJ. The significance of keratinizing squamous cell histology in Chinese patients with nasopharyngeal carcinoma. Clin. Oncol.10, 161–164 (1998).
   Google Scholar
• Moss DJ, Chan SH, Burrows SR et al. Epstein–Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int. J. Cancer32, 301–305 (1983).
   PubMed Web of Science ®Google Scholar
• Chua D, Huang J, Zheng B et al. Adoptive transfer of autologous Epstein–Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer94, 73–80 (2001).
   PubMed Web of Science ®Google Scholar
• Straathof KC, Bollard CM, Popat U et al. Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes. Blood105, 1898–1904 (2005).
   PubMed Web of Science ®Google Scholar
• Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein–Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol.23, 8942–8949 (2005).
   PubMed Web of Science ®Google Scholar
• Lofgren LA, Hallgren S, Nilsson E et al. Photodynamic therapy for recurrent nasopharyngeal carcinoma. Arch. Otolaryngol. Head Neck Surg.121, 997–1002 (1995).
   PubMedGoogle Scholar
• Kulapaditharom B, Boonkitticharoen V. Photodynamic therapy in management of head and neck cancers: a two-year experience. J. Med. Assoc. Thai.79, 229–235 (1996).
   PubMedGoogle Scholar
• Kulapaditharom B, Boonkitticharoen V. Photodynamic therapy in management of head and neck cancers and precancerous lesions. J. Med. Assoc. Thai.83, 249–258 (2000).
   PubMedGoogle Scholar
• Molinari R. European organization for research on treatment of cancer. Controlled trials of chemotherapy as an adjuvant or palliative treatment of nasopharyngeal carcinoma. IARSC Sci. Publ.20, 565–574 (1978).
   Google Scholar
• Au E, Ang PT. A Phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann. Oncol.5, 87–89 (1994).
   PubMed Web of Science ®Google Scholar
• Wang TL, Tang YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann. Acad. Med. Singapore20, 601–603 (1991).
   PubMedGoogle Scholar
• Au E, Tan PH, Ang PT. Activity of paclitaxel by three hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal carcinoma. Ann. Oncol.9, 327–329 (1998).
   PubMed Web of Science ®Google Scholar
• Tan EH, Khoo KS, Wee J et al. Phase II trial of paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann. Oncol.10, 235–237 (1999).
   PubMed Web of Science ®Google Scholar
• Yeo W, Leung TW, Chan AT et al. A Phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur. J. Cancer34, 2027–2031 (1998).
   PubMed Web of Science ®Google Scholar
• Boussen H, Cvitkovic E, Wendling JL et al. Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J. Clin. Oncol.9, 1675–1681 (1991).
   PubMed Web of Science ®Google Scholar
• Hasbini A, Mahjoubi R, Fandi A et al. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type. Ann. Oncol.10, 421–425 (1999).
   PubMed Web of Science ®Google Scholar
• Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A Phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer73, 247–252 (1994).
   PubMed Web of Science ®Google Scholar
• Gebbia V, Zerillo G, Restivo G et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases. Br. J. Cancer68, 191–194 (1993).
   PubMed Web of Science ®Google Scholar
• Azli N, Fandi A, Bachouchi M et al. Final report of a Phase-II study of chemotherapy with bleomycin, epirubicin and cisplatin for locally advanced and metastatic/recurrent UCNT. Cancer J. Sci. Am.1, 222–229 (1995).
   PubMedGoogle Scholar
• Dodion P, Cognetti F, Rymenant M, Dalesio O, Kirkpatrick A, Rozecweig C. Phase-II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of head and neck. Eur. J. Cancer Clin. Oncol.22, 241–243 (1986).
   PubMedGoogle Scholar
• Fountzilas G, Danilidis J, Sridhar K et al. Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of head and neck region. Cancer66, 1453–1460 (1990).
   PubMed Web of Science ®Google Scholar
• Cvitkovic E, Mahjoubi R, Lianes P et al. 5FU, mitomycin, epirubicin and cisplatin in recurrent and/or metastatic UCNT. Proc. Am. Soc. Clin. Oncol.10, 200 (1991).
   Google Scholar
• Fandi A, Taama A, Azli N et al. Palliative treatment with low-dose continous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type. Head Neck19, 41–47 (1997).
   PubMedGoogle Scholar
• Foo KF, Tan EH, Leong SS et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann. Oncol.13, 150–156 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother. Pharmacol.61, 33–38 (2008).
   PubMed Web of Science ®Google Scholar
• Poon D, Chombay B, Cheung YB, Leong SS, Tan EH. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer103, 576–581 (2005).
   PubMedGoogle Scholar
• Chua DT, Sham JS, Au GK. A Phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol.39, 361–366 (2003).
   PubMed Web of Science ®Google Scholar
• Chua DT, Wei WI, Sham JS. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn. J. Clin. Oncol.38, 244–249 (2008).
   PubMed Web of Science ®Google Scholar
• Taamma A, Fandi A, Azli N et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin and cisplatin for patients with locally advanced, metastatic or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer86, 1101–1108 (1999).
   PubMedGoogle Scholar
• Chua DT, Kwong DL, Sham JS, Au GK, Choy D. A Phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur. J. Cancer36, 736–741 (2000).
   PubMedGoogle Scholar
• Ngan RK, Yiu HH, Lau WH et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a Phase II study. Ann. Oncol.13, 1252–1258 (2002).
   PubMed Web of Science ®Google Scholar
• Airoldi M, Pedani F, Marchionatti S et al. Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori88, 273–276 (2002).
   PubMedGoogle Scholar
• Leong SS, Wee J, Rajan S et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer113, 1332–1337 (2008).
   PubMed Web of Science ®Google Scholar
• Wang CC, Chang JY, Liu TW, Lin CY, Yu YC, Hong RL. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck28, 74–80 (2006).
   PubMed Web of Science ®Google Scholar
• Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kamayama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx29, 175–181 (2002).
   PubMed Web of Science ®Google Scholar
• Zheng X, Hu L, Chen F, Christensson B. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein–Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur. J. Cancer B. Oral Oncol.30B, 290–295 (1994).
   PubMedGoogle Scholar
• Roychowdhury DF, Tseng A, Fu KK, Weinburg V, Weidner N. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and C-erbB2 expression. Cancer77, 1419–1426 (1996).
   PubMed Web of Science ®Google Scholar
• Sheen TS, Huang YT, Chang YL et al. Epstein–Barr virus-encoded latent membrane protein co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J. Cancer Res.90, 1285–1292 (1999).
   PubMedGoogle Scholar
• Leong JL, Loh KS, Putti TC, Goh BC, Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope114, 153–157 (2004).
   PubMedGoogle Scholar
• Putti TC, To KF, Hsu HC et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicenter immunohistochemical study in the Asia–Pacific region. Histopathology41, 144–151 (2002).
   PubMedGoogle Scholar
• Ma BB, Poon TC, To KF et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma: a prospective study. Head Neck25, 864–872 (2003).
   PubMed Web of Science ®Google Scholar
• Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.59, 11–20 (2004).
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC et al. Multicenter, Phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol.23, 3568–3576 (2005).
   PubMed Web of Science ®Google Scholar
• Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck30, 863–867 (2008).
   PubMed Web of Science ®Google Scholar
• Guang-Wu H, Sunagawa M, Jie-En L et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope110, 2066–2069 (2000).
   PubMed Web of Science ®Google Scholar
• Wakisaka N, Wen QH, Yoshizaki T et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope109, 810–814 (1999).
   PubMedGoogle Scholar
• Elser C, Siu LL, Winquist E et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol.25, 3766–3773 (2007).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360, 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A et al. FLEX Study Team cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet373(9674), 1525–1531 (2009).
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan LY, Lo KW et al. Quantitative analysis of cell-free Epstein–Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res.59, 1188–1191 (1999).
   PubMed Web of Science ®Google Scholar
• Lo YM, Leung SF, Chan LY et al. Kinetics of plasma Epstein–Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer60, 2351–2355 (2000).
   Google Scholar
• Lo YM, Leung SF, Chan LY et al. Plasma cell-free Epstein–Barr virus DNA quantitation in patients with nasopharyngeal carcinoma: correlation with clinical staging. Ann. NY Acad. Sci.906, 99–101 (2000).
   PubMedGoogle Scholar
• Lo YM, Chan LY, Chan AT et al. Quantitative and temporal correlation between circulating cell-free Epstein–Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res.59, 5452–5455 (1999).
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan AT, Chan LY et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein–Barr virus DNA. Cancer Res.60, 6878–6881 (2000).
   PubMed Web of Science ®Google Scholar
• Makitie AA, Resi PP, Irish J et al. Correlation of Epstein–Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck26, 815–822 (2004).
   PubMedGoogle Scholar
• Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res.61, 1659–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Chan AT, Lo YM, Zee B et al. Plasma Epstein–Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst.94, 1614–1619 (2002).
   PubMed Web of Science ®Google Scholar